New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
08:47 EDTEPZMEpizyme price target raised to $52 from $37 at Wedbush
Wedbush increased its price target on Epizyme after the company released clinical data on its EPZ-5676 treatment that the firm views as positive. The firm reiterates an Outperform rating on the stock.
News For EPZM From The Last 14 Days
Check below for free stories on EPZM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
14:45 EDTEPZMNew Enterprise Associates reports 15.4% stake in Epizyme
Subscribe for More Information
August 15, 2014
10:12 EDTEPZMEpizyme management to meet with Leerink
Subscribe for More Information
August 13, 2014
07:33 EDTEPZMEpizyme reports Q2 EPS (40c), consensus (50c)
Reports Q2 revenue $9.49M, consensus $7.58M. Expects to end 2014 with more than $170M in cash and cash equivalents, it believes will fund the company until at least mid-2016, prior to including any potential future milestone payments.
August 12, 2014
17:12 EDTEPZMEpizyme reports MTD not reached in 3 dose cohorts from EPZ-6438 Phase 1 trial
Subscribe for More Information
15:56 EDTEPZMEpizyme rises 5.3% to $35.93
A late day move higher in shares of Epizyme came in concert with the posting of a presentation dated August 12, entitled "EZH2 Inhibitor EPZ-6438 (E7438) in Non-Hodgkin Lymphoma: Pre-Clinical Models and Early Clinical Observations," to the company's website. Reference Link
15:23 EDTEPZMNotable companies reporting before tomorrow's open
Subscribe for More Information
August 11, 2014
06:54 EDTEPZMAmerican Society of Hematology to hold a meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use